Blood Cancer – Page 2

Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US regulatory body placed the experiments on full clinical hold, according to a company statement.

Gilead Sciences puts last-stage blood cancer trials on hold after FDA order

HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.

by HealthQuill
February 8, 2024
0 Comments

Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss firm access to a key drug for treating blood cancer.

Drugs Health Pharma

Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio

HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.

by HealthQuill
February 6, 2024
0 Comments

Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood cancer drug Jaypirca.

Drugs Health Pharma

Eli Lilly’s drug gets second FDA nod for treating blood cancer in adults

HQ Team December 4, 2023: Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood.

by HealthQuill
December 4, 2023
0 Comments

US scientists have honed in on a single chimeric antigen receptor T-cell (CAR T) therapy to cure all forms of blood cancer.

Drugs Health Pharma

US scientists zero in on single blood cancer therapy in animal studies

HQ Team September 28, 2023: US scientists have honed in on a single chimeric antigen receptor T-cell (CAR T) therapy to cure all.

by HealthQuill
September 28, 2023
0 Comments

The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of the bone marrow.

Drugs Health Pharma

EMA recommends stopping sale of GSK’s blood cancer drug in EU

The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.

by HealthQuill
September 15, 2023
0 Comments

The USFDA has granted accelerated approval for Pfizer Inc’s Elrexfio to treat incurable blood cancer, multiple myeloma, that affects plasma cells made in the bone marrow, according to a company statement.

Drugs Health Pharma

US regulator approves Pfizer’s Elrexfio to treat multiple myeloma

HQ Team August 15, 2023: The USFDA has granted accelerated approval for Pfizer Inc’s Elrexfio to treat incurable blood cancer, multiple myeloma, that.